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Background: Many MetS related biomarkers had been discovered, which provided the possibility for building the
MetS prediction model. In this paper we aimed to develop a novel routine biomarker-based risk prediction model
for MetS in urban Han Chinese population.
Methods: Exploring Factor analysis (EFA) was firstly conducted in MetS positive 13,345 males and 3,212 females
respectively for extracting synthetic latent predictors (SLPs) from 11 routine biomarkers. Then, depending on the
cohort with 5 years follow-up in 1,565 subjects (male 1,020 and female 545), a Cox model for predicting 5 years
MetS was built by using SLPs as predictor; Area under the ROC curves (AUC) with 10 fold cross validation was used
to evaluate its power. Absolute risk (AR) and relative absolute risk (RAR) were calculated to develop a risk matrix for
visualization of risk assessment.
Results: Six SLPs were extracted by EFA from 11 routine health check-up biomarkers. Each of them reflected the
specific pathogenesis of MetS, with inflammatory factor (IF) contributed by WBC & LC & NGC, erythrocyte parameter
factor (EPF) by Hb & HCT, blood pressure factor (BPF) by SBP & DBP, lipid metabolism factor (LMF) by TG & HDL-C,
obesity condition factor (OCF) by BMI, and glucose metabolism factor (GMF) by FBG with the total contribution of
81.55% and 79.65% for males and females respectively. The proposed metabolic syndrome synthetic predictor (MSP)
based predict model demonstrated good performance for predicting 5 years MetS with the AUC of 0.802 (95% CI
0.776-0.826) in males and 0.902 (95% CI 0.874-0.925) in females respectively, even after 10 fold cross validation,
AUC was still enough high with 0.796 (95% CI 0.770-0.821) in males and 0.897 (95% CI 0.868-0.921) in females. More
importantly, the MSP based risk matrix with a series of risk warning index provided a feasible and practical tool for
visualization of risk assessment in the prediction of MetS.
Conclusions: MetS could be explained by six SLPs in Chinese urban Han population. The proposed MSP based
predict model demonstrated good performance for predicting 5 years MetS, and the MetS-based matrix provided a
feasible and practical tool.
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Metabolic syndrome (MetS) is a disorder with co-
occurrence of several known cardiovascular risk factors,
including insulin resistance, obesity, atherogenic dyslip-
idemia and hypertension [1]. With the economic devel-
opment and the changing of people's lifestyle in china,
the prevalence of MetS is increasing rapidly. Compared
with Europeans and Americans, Asians are more likely
to have MetS [2]. Data from the China Health and
Nutrition Survey conducted in 2009 suggested that
the prevalence rate of MetS has reached up to 21.3%
among the Chinese adults [3]. Many studies indicated
that incidence of MetS will increase the risk of type 2
diabetes [4], cardiovascular disease [5-9], renal damage
[10,11], and so on. Therefore, prediction of MetS is very
essential for early prevention of the above diseases.
Some risk scores based on cross-sectional studies were
structured for screening undiagnosed MetS [12-14], which
depended on questionnaire survey about participants’ life-
style and medical histories. Although the area under the
ROC curves for detecting the MetS in these studies
were acceptable with a range from 72.4% to 80.1%,
cross-sectional study could only provide temporal in-
formation of the subjects. Cohort study is more pref-
erable for risk assessment. Hsiao and Yang conducted
a two-year (from 2003 to 2005) [15] and a 5-year follow-
up study (during 1997–2006) [16] respectively in Chinese
population. Both of them confirmed that routine check-
up biomarkers like serum cholesterol, triglycerides, blood
glucose, measurement of body height and weight, blood
pressure et al., could be served as effective predictors to
MetS using multivariate logistic regression (MLR). How-
ever, MLR is not suitable for survival data, and it also
limited the applying of the model in the first study due to
relative short follow-up time and small sample. In the sec-
ond study stepwise regression has ruled out many MetS
related biomarkers from the model. Fortunately, many
other studies [17-29] have found a number of MetS re-
lated biomarkers, which provide us a convenience to build
the risk appraisal model of MetS. After studying 6Syn-
thetic Latent Predictors from 11 MetS routine biomarkers
in a MetS positive population, we develop a novel routine




Subjects were selected from the urban adult citizen who
came to the Center for Health Management of Shandong
Provincial QianFoShan Hospital, and the Health Examin-
ation Center of Shandong Provincial Hospital to conduct
medical examination from 2005 to 2010. Among 92,284
subjects (aged 18 to 82 years) completing all steps of
physical examination, 16,557 subjects were diagnosedwith MetS at their first check-up year according to the
criteria of the Chinese Medical Association. Of 75,727
subjects without MetS at baseline, 1,565 (1,020 males
and 545 females) completed a 5-year follow-up and
were included in the cohort study design. The cumula-
tive incidence rate was calculated for 1,565 subjects who
were followed up.
Biomarkers selection and measurements
In the present study, eleven biomarkers were selected
from routine health check-up data, including body mass
index (BMI), systolic blood pressure (SBP), diastolic blood
pressure (DBP), fasting blood-glucose (FBG), triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C), he-
moglobin (Hg), hematocrit (HCT), white blood cell count
(WBC), lymphocyte (LC), neutrophile granulocyte (NGC).
Among them, BMI, SBP, DBP, TG, HDL-C and FBG were
selected based on the traditional definition of MetS. The
others were included according to the available results of
peer studies: Hb [17-19], HCT [17,18,28], WBC [20-27],
LC [23,29], NGC [23,29]. All measurements were conduc-
ted in the Center for Health Management of Shandong
Provincial QianFoShan Hospital and the Health Examin-
ation Center of Shandong Provincial Hospital following
same and standard procedures. Both of the two insti-
tutions are nationally accredited. The whole study was
approved by the Ethics Committee of School of Public
Health, Shandong University, and written informed con-
sent was obtained from all eligible participants.
Definition of MetS
Chinese Medical Association Diabetes Branch criteria
[30] were applied to define MetS in this paper. Sub-
jects who had three or more of the following four
signs were diagnosed with MetS: 1) overweight or
obesity, BMI ≥25.0 Kg/M2; 2) hypertension, systolic/
diastolic ≥140 mmHg/90 mmHg or previous diagno-
sis; 3) dyslipidemia, fasting TG ≥1.7 mmol/L (110 mg/
dl), or fasting high-density lipoprotein cholesterol (HDL-
C) <0.9 mmol/L (35 mg/dl); 4) hyperglycemia, fasting
blood-glucose (FBG) ≥6.1 mmol/L(110 mg/dl) or 2 h
Post-meal glucose (PG) ≥7.8 mmol/L(140 mg/dl), or pre-
vious diagnosis.
Statistical analysis
Descriptive statistics were conducted for 16,557 subjects
with MetS at baseline. Student's t test was used to detect
the statistical significances for 11 biomarkers between
males and females, and the χ2 test was conducted to
detect the difference in the prevalence of the four basic
components (obesity, hypertension, dyslipidemia and hy-
perglycemia) between males and females.
To eliminate multicollinearity between the routine
check-up biomarkers and build a better model for MetS
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proportional hazard regression model are applied in the
present study. Finally, a MetS synthetic predictor (MSP)
was developed through the following four steps: First,
EFA with principal component algorithm and varimax
rotation from correlation matrix was performed to ex-
tract independent MetS risk-related factors from the 11
routine check-up biomarkers in 16,557 subjects with
MetS at baseline. The criteria for retaining factors in the
present study was eigenvalue >0.9 (for keeping the ac-
counting variations of total was greater than 70%). Only
variables that share a factor loading of at least 0.50 were
used for further analytical interpretation and named fac-
tors. Second, a Cox regression model was built between
the hazard function of MetS and the extracted factors in
1,565 subjects in the cohort study design: h(t) = h0(t)exp
(β0age + β1F1 + β2F2 +… + βkFk), and a MSP was devel-
oped by MSP = β1F1 + β2F2 +… + βkFk. Third, the risk of
MetS, for the 1565 subjects from the cohort, was esti-
mated by
P tð Þ ¼ 1−S tð Þ ¼ 1− exp −
Z t
0
h0 uð Þ exp Bð Þdu
 
ð1Þ
where, P(t) was the predictive probability of MetS at
year t, B = β0age + β1MSP. For both training set and 10
fold cross validation, Receiver Operator Characteristics
curve (ROC curve) analysis was conducted, and the area
under the ROC curve (AUC) together with sensitivity,
specificity, 95% Confidence Interval and cut-off of P
value was calculated by MedCalc software [31]. The op-
timal cut-off was estimated based on the Youden index
criterion [32] which is optimal in the sense that it pro-
vides a score which reflects the intention of maximizing
the overall correct classification rate. Finally, Excess
Absolute Risk (EAR) and Relative Absolute Risk(RAR)
were calculated for 1,565 subjects from the five-year
follow-up who had completed physical examinations
and the 11 biomarker measurements by EAR ¼ Pj tð Þ−Pj
tð Þ and RAR ¼ Pj tð Þ=Pj tð Þ respectively, where Pj(t) signi-
fied Absolute Risk (AR), namely the probability of MetS
at year t, in which j noted subject’s age. Pj tð Þ signified
the average probability of MetS at year t in jth age, which
can be calculated by model (1) through Bj ¼ β1agej þ γ
MSPj, where MSPj was the mean of MSP in jth age. All
the steps were conducted in males and females respect-
ively. The risk matrix for AR and RAR were depicted
using ArcGIS 9.1, and all statistical analyses was perfor-
med using SAS 9.1.3 with P < 0.05 considered statisti-
cally significant.
Results
The prevalence of MetS in the study was 17.9% (16,557/
92,284) (22.7% in males and 9.6% in females) at baseline.At the end of the follow-up period of 1,565 subjects, 348
incident MetS cases (286 males and 62 females) were
diagnosed and the cumulative incidence rate was 22.2%
(28% in males and 11.4% in females) (see Additional
file 1: Table S1). The prevalence of four basic com-
ponents (obesity, hypertension, hyperglycemia, and dysli-
pidemia) was significantly different between males and
females (see Additional file 2: Table S2).
Table 1 showed the distribution of age and eleven bio-
markers between males and females with MetS at base-
line, indicating that all variables except BMI and LC
were significantly different between males and females.
Of them, DBP, TG, Hb, HCT, WBC and NGC were
higher in males than in females, while age, SBP, FBG,
and HDL-C were higher in females than in males. Cor-
relation matrix between 11 biomarkers was illustrated in
Additional file 3: Table S3. The results of EFA were
showed in Table 2 with explained variance and cumula-
tive variance, this suggested that six synthetic latent pre-
dictors (SLPs) could explain 81.55% and 79.65% of total
variance for males and females respectively. According
to the criteria of analytical interpretation stated in the
statistical analysis section, they were named as inflamma-
tory factor (IF), erythrocyte parameter factor (EPF), blood
pressure factor (BPF), lipid metabolism factor (LMF),
obesity condition factor (OCF), and glucose metabolism
factor (GMF) in both males and females. Of the six SLPs,
IF was contributed by WBC & LC & NGC, EPF by Hb &
HCT, BPF by SBP & DBP, LMF by TG & HDL-C, OCF by
BMI, and GMF by FBG.
Figure 1 showed the result of ROC analysis to predict
5-year risk of MetS by the proposed predict model. It
indicated that the AUC was up to 80.2% and 90.2% for
males and females respectively in training set (seeing
Figure 1A and 1B). While 79.6% and 89.7% after 10 fold
cross validation.
Figure 2 showed the 5-year AR matrix and RAR
matrix for MetS by gender in the cohort (n = 1,565), spe-
cifically Figure 2A1 and 2A2 for males, and Figure 2B1
and 2B2 for females. These matrices provide a conveni-
ent tool for conducting MetS prediction in health man-
agement and clinical practice. For example, a man aged
30-year-old and having AR of 0.233 has an EAR of 0.054
(0.233-0.179) and RAR of 1.301 (0.233/0.179), while a
man aged 60-year-old and having an AR of 0.233, has
the EAR −0.187 (0.233-0.420) and RAR of 0.555 (0.233/
0.420). These show that although their predictive prob-
abilities for MetS over 5 years are the same, the younger
man has a higher MetS risk compared to his peers,
about 1.301 times than that of the average risk of
40-year-old population, indicating that changes in
lifestyles and social intervention strategies are needed
for him. Alternatively the MetS risk of the older man is
lower than the average risk of the same age, only 55.5% of
Table 1 Distribution of age and the eleven biomarkers between male and female with baseline metabolic syndrome
Male (n = 13345) Female (n = 3212) P values
Mean ± SD Mean ± SD
Age (years) 49.00 ± 13.09 59.50 ± 12.49 <.0001
body mass index (kg/m2) 28.29 ± 2.99 28.27 ± 3.10 0.8241
systolic blood pressure (mmHg) 144.60 ± 17.28 150.40 ± 20.54 <.0001
diastolic blood pressure (mmHg) 87.09 ± 12.00 81.76 ± 11.99 <.0001
fasting blood-glucose (mmol/L) 6.43 ± 1.94 6.65 ± 2.09 <.0001
triglycerides (mmol/L) 2.87 ± 2.26 2.42 ± 1.53 <.0001
high-density lipoprotein cholesterol (mmol/L) 1.18 ± 0.35 1.32 ± 0.35 <.0001
hemoglobin (g/L) 157.70 ± 10.82 138.30 ± 11.88 <.0001
hematocrit (%) 46.27 ± 3.03 41.65 ± 3.18 <.0001
white blood cell count (109/L) 7.18 ± 1.67 6.90 ± 1.63 <.0001
lymphocyte (109/L) 2.25 ± 0.69 2.24 ± 0.68 0.4432
neutrophile granulocyte (109/L) 4.30 ± 1.28 4.13 ± 1.27 <.0001
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he has a good health status compared with his peers.
Using the cut-off points showed in Figure 1A for males
(0.2749) and Figure 1B for females (0.1181), people were
classified as high-risk population (> the cut-off point value)
or low-risk population (≤ the cut-off point value). The pro-
portion of high-risk that comes with ageing in the general
population (n = 92284) was drawn in Figure 3. Generally,
the proportion of high risk subjects increase with age in
both males and females. Nevertheless, the proportion of
high-risk was higher in males than females before the
age of 55, while it was the reverse after 55.Table 2 Factor loadings by principal component analysis with
in MetS patients
Males (n = 13345)
IF EPF BPF LMF OCF
BMI 0.050 0.017 0.108 −0.042 0.954
SBP 0.031 −0.088 0.885 −0.051 −0.007
DBP 0.001 0.206 0.813 0.122 0.134
FBG −0.001 −0.017 −0.049 0.111 0.008
TG 0.066 0.051 −0.032 0.825 0.171
HDL-C −0.050 −0.043 0.093 0.794 −0.239
Hb 0.045 0.971 0.051 0.021 0.010
HCT 0.119 0.957 0.041 −0.012 0.017
WBC 0.991 0.078 0.035 −0.020 0.010
LC 0.642 0.033 −0.072 0.127 0.117
NGC 0.853 0.073 0.086 −0.094 −0.058
% Variance explained 22.15 15.87 13.34 12.93 8.88
Cumulative variance 22.15 38.03 51.37 64.30 73.18
BMI indicated body mass index; SBP, systolic blood pressure; DBP, diastolic blood p
lipoprotein cholesterol; Hb, hemoglobin; HCT, hematocrit; WBC, white blood cell co
as inflammatory factor (IF), erythrocyte parameter factor (EPF), blood pressure facto
metabolism factor (GMF). The bold character figures were factor loadings greater thDiscussions
The routine health check-up based biomarkers for
predicting MetS
Currently, several potential routine health check-up
based biomarkers, such as Hb [17-19], HCT [17,18,28],
WBC [20-27], LC [23,29] and NGC [23,29], were identified
for predicting MetS/its components. Correlation matrix
between 11 biomarkers was illustrated in Additional file 3:
Table S3, which Shows the necessity of EFA. In this paper,
we extracted 6 independent synthetic latent predictors
(SLPs) by EFA from 11 routine health check-up biomarkers
(BMI, SBP, DBP, FBG, TG, HDL-C, Hb, HCT, WBC, LC,varimax rotation on 11 routine health check-up biomarkers
Females (n = 3212)
GMF IF EPF BPF LMF OCF GMF
0.007 0.016 0.001 0.184 0.080 0.873 −0.013
0.039 0.018 −0.019 0.851 0.013 0.015 0.023
−0.101 0.005 0.155 0.786 −0.012 0.120 −0.065
0.965 0.074 0.038 −0.041 0.165 0.004 0.905
0.087 0.013 0.067 −0.045 0.776 0.082 0.199
0.027 −0.076 −0.039 0.131 0.583 −0.546 −0.027
0.018 0.047 0.975 0.071 0.028 0.009 0.055
−0.040 0.095 0.969 0.074 0.045 0.013 −0.017
0.036 0.992 0.076 0.014 0.045 0.033 0.013
−0.176 0.592 0.086 −0.031 0.410 0.109 −0.317
0.144 0.881 0.040 0.033 −0.173 −0.025 0.197
8.37 22.21 16.21 13.15 11.12 9.01 7.95
81.55 22.21 38.42 51.57 62.69 71.70 79.65
ressure; FBG, fasting blood-glucose; TG, triglycerides; HDL-C, high-density
unt; LC, lymphocyte; NGC, neutrophile granulocyte; Factor1-Factor6 was called
r (BPF), lipid metabolism factor (LMF), obesity condition factor (OCF), glucose
an 0.50.
Figure 1 ROC curve for prediction of metabolic syndrome. A
shows the predictive effect in males, B represents corresponding
result in females. The dotted plots stand for 95% Confidence
Interval. A: Area under the ROC curve (AUC) 0.802; Standard Error
0.0168; 95% Confidence Interval 0.776 to 0.826; z statistic 17.916;
Significance level P (Area = 0.5) 0.0001. Point with the highest
accuracy showed sensitivity 73.4 and specificity 73.3 under the
cut-off 0.2749. B: Area under the ROC curve (AUC) 0.902; Standard Error
0.0264; 95% Confidence Interval 0.874 to 0.925; z statistic 15.233;
Significance level P (Area = 0.5) 0.0001. Point with the highest accuracy
showed sensitivity 87.1 and specificity 83.0 under the cut-off 0.1181.
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but eliminating the multicollinearity between them. Each
SLPs reflected the specific pathogenesis of MetS, with IF
contributed by WBC & LC & NGC, EPF by Hb & HCT,BPF by SBP & DBP, LMF by TG & HDL-C, OCF by BMI,
and GMF by GMF (see Table 2). The cumulative Variances
explained by the six SLPs were up to 81.55% and 79.65%
for males and females respectively. Particularly, the IF
and EPF were identified as the key factors for the vari-
ation of MetS with their contribution proportion of
22.25% &15.87% in males and 22.21%&16.21% in females
respectively. Pathogenically, both of them were strong
associated with insulin resistance [33-36] which was the
‘core’ for MetS [37-39]. EPF was contributed by Hb &
HCT. Hb is a carrier and buffer of nitric oxide (NO), and
various compounds of Hb with NO can affect Hb-oxygen
affinity of the whole blood [40]. Disturbed NO synthesis
may exert an adverse effect on endothelial dysfunction
through the L-arginine-NO pathway [41]. Furthermore,
endothelial dysfunction was reported to be associated with
MetS [42,43]. HCT could change blood viscosity and per-
ipheral resistance to blood flow, and further contribute to
insulin resistance [44-46].
Metabolic syndrome synthetic predictor and its application
in MetS prediction
At the end of the follow-up period, the cumulative inci-
dence rate reach up to 22.2% (28% in males and 11.4%
in females) (see Additional file 1: Table S1). Currently,
three cross-sectional design based risk scores [12-14]
and two cohort design based predictive models [15,16]
had been developed to predict MetS on different ethnici-
ties. Although these predict tools obtain acceptable
power with their AUC ranged from 0.724 to 0.827, their
risk algorithm and visualization of risk assessment still
had development potential for improving power, feasibility
and practicability. In this paper we developed a routine
health check-up cohort design based MetS synthetic
predictor (MSP) for predict 5 year risk of MetS in the
frame work of Cox regression model. The MSP based
predict model demonstrated good performance for pre-
dicting 5 years MetS with the AUC of 0.802 (95% CI
0.776-0.826) in males and 0.902 (95% CI 0.874-0.925) in
females respectively, even after 10 fold cross validation,
AUC was still enough high with 0.796 (95% CI 0.770-
0.821) in males and 0.897 (95% CI 0.868-0.921) in females.
More importantly, the MSP was further used to con-
struct the risk matrix with a series of risk warning in-
dexes including average risk in population, AR & RAR
for subjects, and the cut-off curve for predicted MetS
(see Figure 2). This matrix provided a feasible and prac-
tical tool for visualization of risk assessment in the predic-
tion of MetS. As an example, for a woman at a given age
who receives health check-up, the risk matrices can pro-
vide her with AR (Figure 2B1) and RAR (Figure 2B2) com-
pared with the average hazard within the same age group
in females, this may urge her to intervene risk factors for
reducing risk of MetS.
Figure 2 The 5-year risk matrix for risk appraisal of metabolic syndrome by gender. A1 and B1 are absolute risk matrix of male and
female respectively. A2 and B2 are relative absolute risk matrix of male and female respectively. For male: MetS Predictor (MSP) = 0.451604BMI +
0.313187SBP + 0.250746DBP +0.670039 FB G + 0.120262TG-0.06067HLD_C+ 0.042693Hb + 0.003179HCT + 0.064581WBC-0.08385LC + 0.126292NGC. For
female: MetS Predictor (MSP) = 0.711655BMI + 0.266298SBP + 0.290385DBP + 0.392424FBG+ 0.482012TG-0.09606HLD_C + 0.116441Hb + 0.10335HCT +
0.07158WBC+ 0.160117LC-0.0048NGC.
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The proportion of subjects with high-risk was higher in
males than females before the age of 55, while it was in
reverse after 55 (showed in Figure 3). Similar results have
been obtained in the Korean population [47] with the de-
marcation point of 60 years old. In particular, the patterns
of subjects with high-risk were quite different between
males and females. The proportion of subjects with high-risk increased linearly with age in male population, while
showed an S shaped curve in female population with the
fastest growth period from 40 to 60 years old. This dif-
ference may be associated with women’s menopause.
Various studies indicated that natural menopause was
associated with increased central adiposity [48], blood
pressure [49-55], total cholesterol, LDL cholesterol and
triglyceride levels [50,56], which would further increase
Figure 3 The metabolic syndrome risk appraisal result of 92284 subjects in routine health check-up system.
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The contribution of several metabolic components to
the metabolic syndrome is different in males and females
(see Additional file 2: Table S2).
We re-assessed the predictive ability using IF & EPF
alone and four classical MetS components respectively.
Additional file 4: Table S4 showed these results, as ex-
pected, our proposed 6 SLPs still have the best perform-
ance. Actually, in China, health check up was embedded
in “physical examination package” and usually the biomar-
kers can be obtained together. The Chinese government
request every Health Examination Center that at least all
biomarkers used in this manuscript must be tested during
the health examination process.Limitations
Study population was just employed urban residents,
therefore the results may not extend to general popula-
tion. In addition, five years follow-up was relatively short
for predict long term risk of MetS.Conclusions
In conclusion, MetS could be explained by six SLPs in
Chinese urban Han population. The proposed MSP
based predict model demonstrated good performance
for predicting 5 years MetS, and the MetS-based matrix
provided a feasible and practical tool for visualization of
risk assessment in the prediction of MetS.Additional files
Additional file 1: Table S1. The incidence rate of MetS in unaffected
1,565 subjects at baseline after a follow-up of five years.
Additional file 2: Table S2. The prevalence of the 4 basic components
for both male and female metabolic syndrome groups.
Additional file 3: Table S3. Correlation matrix between eleven
biomarkers.
Additional file 4: Table S4. The area under the ROC curves (AUC) by
using different MetS predictors.
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